Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMBJ
576
Embraer S.A. ADS
EMBJ
$13.2B
| $28M | 0.04% |
1,456,200
-131,600
| -8% | -$2.57M |
|
577
Stellantis
STLA
$20.2B
| $28M | 0.04% |
3,084,087
+505,518
| +20% | +$3.78M |
|
|
PXD
578
DELISTED
Pioneer Natural Resource Co.
PXD
| $27.9M | 0.04% |
154,888
-258,500
| -63% | -$47.4M |
|
579
Central Garden & Pet Co Class A
CENTA
$2.41B
| $27.8M | 0.04% |
1,126,500
+113,500
| +11% | +$2.46M |
|
|
GK
580
DELISTED
G&K Services Inc
GK
| $27.8M | 0.04% |
288,595
+78,205
| +37% | +$7.48M |
|
|
RPXC
581
DELISTED
RPX Corporation
RPXC
| $27.8M | 0.04% |
2,577,100
+196,500
| +8% | +$2.06M |
|
|
RDUS
582
DELISTED
Radius Recycling
RDUS
| $27.8M | 0.04% |
1,080,096
+1,300
| +0.1% | +$33.4K |
|
583
HEICO Corp Class A
HEI.A
$38.1B
| $27.7M | 0.04% |
994,795
+427,490
| +75% | +$11.1M |
|
|
FRP
584
DELISTED
Fairpoint Communications, Inc.
FRP
| $27.6M | 0.04% |
1,477,800
+422,200
| +40% | +$7.12M |
|
585
National Fuel Gas
NFG
$7.75B
| $27.6M | 0.04% |
487,800
-11,700
| -2% | -$640K |
|
|
IDTI
586
DELISTED
Integrated Device Technology I
IDTI
| $27.6M | 0.04% |
1,170,900
-1,825,953
| -61% | -$42.1M |
|
|
TCF
587
DELISTED
TCF Financial Corporation
TCF
| $27.6M | 0.04% |
1,408,100
-427,600
| -23% | -$7.05M |
|
|
DDC
588
DELISTED
Dominion Diamond Corporation
DDC
| $27.6M | 0.04% |
2,848,898
+522,300
| +22% | +$4.77M |
|
589
Ross Stores
ROST
$78.6B
| $27.5M | 0.04% |
+419,328
| New | +$27.4M |
|
590
Repligen
RGEN
$9.45B
| $27.5M | 0.04% |
891,600
-186,100
| -17% | -$5.76M |
|
|
QEP
591
DELISTED
QEP RESOURCES, INC.
QEP
| $27.4M | 0.04% |
1,487,000
+802,300
| +117% | +$14.6M |
|
592
Ituran Location and Control
ITRN
$1.06B
| $27.4M | 0.04% |
1,032,100
+26,200
| +3% | +$679K |
|
593
Jack in the Box
JACK
$358M
| $27.3M | 0.04% |
+244,700
| New | +$25M |
|
594
Banco Santander Chile
BSAC
$16.1B
| $27.3M | 0.04% |
1,248,927
+219,000
| +21% | +$4.79M |
|
|
PDLI
595
DELISTED
PDL BioPharma, Inc.
PDLI
| $27.3M | 0.04% |
12,875,700
-597,154
| -4% | -$1.67M |
|
|
NVMI
596
Nova
NVMI
$13.1B
| $27.3M | 0.04% |
2,071,300
+90,741
| +5% | +$1.14M |
|
|
LMNX
597
DELISTED
Luminex Corp
LMNX
| $27.2M | 0.04% |
1,346,340
+12,100
| +0.9% | +$252K |
|
598
New Oriental
EDU
$8.33B
| $27.2M | 0.04% |
646,400
-135,400
| -17% | -$6.38M |
|
599
TC Energy
TRP
$65.8B
| $27.2M | 0.04% |
602,203
+215,000
| +56% | +$9.76M |
|
|
TYPE
600
DELISTED
Monotype Imaging Holdings Inc.
TYPE
| $27.2M | 0.04% |
1,368,200
+129,700
| +10% | +$2.61M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.